This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Firms at The Oxford Science Park playing important role in COVID-19 response

Firms at The Oxford Science Park playing important role in COVID-19 response

20 Apr 2020

Firms at The Oxford Science Park playing important role in COVID-19 response From immunology research tools and sequencing to AI and cloud telephony Oxford, UK, April 20 2020 – Several occupiers at The Oxford Science Park, one of the UK’s leading parks for science and technology companies, are involved in the response to the COVID-19 epidemic, including important R&D and clinical support services. Part of the broader crisis response across... Read more

Exscientia – joint initiative to identify COVID-19 drugs with Diamond Light Source & Scripps Research

Exscientia – joint initiative to identify COVID-19 drugs with Diamond Light Source & Scripps Research

31 Mar 2020

Exscientia announces joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research   ·       Transatlantic partnership seeks to identify COVID-19 antiviral treatments ·       Exscientia to screen nearly every known approved and investigational drug – 15,000 clinical molecules – against key COVID-19 drug targets to progress rapid... Read more

Lilly and Sitryx Announce Licensing & Research Collaboration to Discover & Develop New Immunometabolic Medicines

Lilly and Sitryx Announce Licensing & Research Collaboration to Discover & Develop New Immunometabolic Medicines

31 Mar 2020

                                                                                                         Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and... Read more

EVOX THERAPEUTICS AND TAKEDA SIGN MULTI-TARGET RARE DISEASE COLLABORATION

EVOX THERAPEUTICS AND TAKEDA SIGN MULTI-TARGET RARE DISEASE COLLABORATION

26 Mar 2020

Evox Therapeutics Ltd (“Evox” or the “Company”), a leading exosome therapeutics company, is pleased to announce the signing of a rare disease-focused partnership with Takeda Pharmaceutical Company Limited (“Takeda”). The multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies, including Evox’s preclinical programme in Niemann-Pick disease type C (NPC) and a second new programme... Read more

Immunocore Secures $130 Million Series B Financing

Immunocore Secures $130 Million Series B Financing

02 Mar 2020

Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic (Oxfordshire, UK and Conshohocken, Pa. and Rockville, Md., US, 2 March 2020)Immunocore, a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More